Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes, finds a recent study. Led by investigators of the ...
Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib with bendamustine and rituximab within its marketing authorisation for untreated mantle cell lymphoma. Anticipate the ...
The bendamustine molecule is composed of 3 structural elements: a mechlorethamine (nitrogen mustard) group, a benzimidazole ring, and a butyric acid side chain (Figure 1). The mechlorethamine ...
Bendamustine is generally well tolerated. The most common serious (grade 3 or 4) adverse events are hematologic in nature. Gastrointestinal events are also commonly observed but are usually mild to ...
A review published in Transfusion Medicine Reviews discussed the 2 therapeutic approaches and their pros and cons for treating cold agglutinin disease (CAD). CAD is a rare hemolytic disorder that ...
Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group A total of 245 courses (median, four ...
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated ...
The authors said their analysis should help clinicians better monitor patients for potential adverse events. A new report has identified new adverse event (AE) signals which the authors say may be ...
Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...
Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial The trial enrolled 31 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results